803 related articles for article (PubMed ID: 33685605)
21. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
Abe N; Bohgaki M; Kasahara H
Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune chronic spontaneous urticaria.
Kolkhir P; Muñoz M; Asero R; Ferrer M; Kocatürk E; Metz M; Xiang YK; Maurer M
J Allergy Clin Immunol; 2022 Jun; 149(6):1819-1831. PubMed ID: 35667749
[TBL] [Abstract][Full Text] [Related]
24. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
25. The Expanding Field of Biologics in the Management of Chronic Urticaria.
Joshi S; Khan DA
J Allergy Clin Immunol Pract; 2017; 5(6):1489-1499. PubMed ID: 28734860
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
[TBL] [Abstract][Full Text] [Related]
27. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
[TBL] [Abstract][Full Text] [Related]
28. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
29. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
30. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
34. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
35. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
36. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Staubach P; Alvaro-Lozano M; Sekerel BE; Maurer M; Ben-Shoshan M; Porter M; Hua E; Ji Y; Burciu A; Savelieva M; Severin T; Drollmann A; Bienczak A
Pediatr Allergy Immunol; 2023 Jul; 34(7):e13982. PubMed ID: 37492920
[TBL] [Abstract][Full Text] [Related]
37. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.
Terhorst-Molawi D; Fox L; Siebenhaar F; Metz M; Maurer M
Am J Clin Dermatol; 2023 May; 24(3):397-404. PubMed ID: 36810982
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
[TBL] [Abstract][Full Text] [Related]
39. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
